Dasatinib(Xspray Pharma)

N/A

Report date: 2025/08/14 11:38:10

Base Information

Drug NameDasatinib(Xspray Pharma)
Drug Alias NameDasynocXS-004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase FYN inhibitorsTyrosine-protein kinase SRC inhibitorsBcr-Abl tyrosine kinase inhibitors +[8] 
TargetsTyrosine-protein kinase FYNEphrin type-A receptor 2Stem cell growth factor receptor +[8] 
Therapy Area/IndicationsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesXspray Pharma AB
China Registration ClassN/A

Develop Information

Active CompaniesXspray Pharma ABEversana Life Science Services LLC
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A